石ヶ坪 良明いしがつぼ よしあき

リウマチ・膠原病－A ベーチェット病関連

• Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
  Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, Melikoğlu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y.
  N Engl J Med. 2019 Nov 14;381(20):1918-1928.
  

  Pubmed

• Clinical manifestations of Behçet's disease depending on sex and age: results from Japanese nationwide registration.
  Ishido T, Horita N, Takeuchi M, Kawagoe T, Shibuya E, Yamane T, Hayashi T, Meguro A, Ishido M, Minegishi K, Yoshimi R, Kirino Y, Kato S, Arimoto J, Ishigatsubo Y, Takeno M, Kurosawa M, Kaneko T, Mizuki N.
  Rheumatology (Oxford). 2017 Nov 1;56(11):1918-1927.
  

  Pubmed

• Continuous evolution of clinical phenotype in 578 Japanese patients with Behcet's disease: a retrospective observational study.
  Kirino Y, Ideguchi H, Takeno M, Suda A, Higashitani K, Kunishita Y, Takase-Minegishi K, Tamura M, Watanabe T, Asami Y, Uehara T, Yoshimi R, Yamazaki T, Sekiguchi A, Ihata A, Ohno S, Ueda A, Igarashi T, Nagaoka S, Ishigatsubo Y, Nakajima H.
  Arthritis Res Ther. 2016 Oct 3;18(1):217.
  

  Pubmed

• Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study.
  Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, Kondo K, Ishigatsubo Y.
  Medicine (Baltimore). 2016 Jun 95(24)
  

  Pubmed

• Clinical value of capsule endoscopy for detecting small bowel lesions in patients with intestinal Behçet's disease.
  Arimoto J, Endo H, Kato T, Umezawa S, Fuyuki A, Uchiyama S, Higurashi T, Ohkubo H, Nonaka T, Takeno M, Ishigatsubo Y, Sakai E, Matsuhashi N, Nakajima A.
  Dig Endosc. 2016 Feb 28(2):179-85.
  

  Pubmed

• Adalimumab in the management of Behçet's disease.
  Ueda A, Takeno M, Ishigatsubo Y.
  Ther Clin Risk Manag. 2015 Apr 13;11:611-9.
  

  Pubmed

• Single center study on ethnic and clinical features of Behcet's disease in Moscow, Russia.
  Lennikov A1, Alekberova Z, Goloeva R, Kitaichi N, Denisov L, Namba K, Takeno M, Ishigatsubo Y, Mizuki N, Nasonov E, Ishida S, Ohno S.
  Clin Rheumatol. 2015 Feb 34(2):321-7.
  

  Pubmed

• Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease.
  Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, Ishigatsubo Y.
  J Neurol Sci. 2015 Jan 10.
  

  Pubmed

• Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy.
  Nakajima Y, Tomita N, Itabashi M, Miyashita K, Watanabe R, Miyazaki T, Tachibana T, Takasaki H, Kawasaki R, Tanaka M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Harano H, Motomura S, Ishigatsubo Y.
  Leuk Res. 2014 Dec 8.
  

  Pubmed

• A novel 8-joint ultrasound score is useful in daily practice for rheumatoid arthritis.
  Yoshimi R, Ihata A, Kunishita Y, Kishimoto D, Kamiyama R, Minegishi K, Hama M, Kirino Y, Asami Y, Ohno S, Ueda A, Takeno M, Ishigatsubo Y.
  Mod Rheumatol. 2014 Nov 17 1-7.
  

  Pubmed

• Adalimumab for the Treatment of Japanese Patients with Intestinal Behçet's Disease.
  Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, Watanabe K, Mitsuyama K, Inoue T, Ishigatsubo Y, Suzuki Y, Nagahori M, Motoya S, Nakamura S, Arora V, Robinson AM, Thakkar RB, Hibi T.
  Clin Gastroenterol Hepatol. 2014 Sep 19. pii: S1542-3565(14)01351-2.
  

  Pubmed

• Immune Reactions in Behçet's Disease.
  Kaneko F, Bang D, Direskeneli RH, Ohno S, Ishigatsubo Y.
  Genet Res Int. 2014 2014:985689.
  

  Pubmed

• Analysis of various factors on the relapse of acute neurological attacks in Behçet's disease.
  Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, Ishigatsubo Y.
  Mod Rheumatol. 2014 Mar 19.
  

  Pubmed

• Single center study on ethnic and clinical features of Behcet's disease in Moscow, Russia.
  Lennikov A, Alekberova Z, Goloeva R, Kitaichi N, Denisov L, Namba K, Takeno M, Ishigatsubo Y, Mizuki N, Nasonov E, Ishida S, Ohno S.
  Clin Rheumatol. 2013 Dec 10.
  

  Pubmed

• Gastrointestinal manifestations of Behçet's disease in Japan: a study of 43 patients.
  Ideguchi H, Suda A, Takeno M, Miyagi R, Ueda A, Ohno S, Ishigatsubo Y.
  Rheumatol Int. 2013 Aug 10.
  

  Pubmed

• Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis.
  Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, Ishigatsubo Y.
  Mod Rheumatol. 2012 Jun;22(3):405-13.
  

  Pubmed

• Characteristics of vascular involvement in Behcet's disease in Japan: a retrospective cohort study.
  Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y.
  Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67):S47-53.
  

  Pubmed

• Clinical Course before and after Cataract and Glaucoma Surgery under Systemic Infliximab Therapy in Patients with Behcet's Disease.
  Nishida T, Shibuya E, Asukata Y, Nakamura S, Ishihara M, Hayashi K, Takeno M, Ishigatsubo Y, Mizuki N.
  Case Report Ophthalmol. 2011 May;2(2):189-92.
  

  Pubmed

• Behcet disease: evolution of clinical manifestations.
  Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y.
  Medicine (Baltimore). 2011 Mar;90(2):125-32.
  

  Pubmed

• Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis.
  Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y.
  Rheumatol Int. 2011 Feb;31(2):243-5.
  

  Pubmed

• Neurological manifestations of Behcet's disease in Japan: a study of 54
  patients.
  Ideguchi H, Suda A, Takeno M, Kirino Y, Ihata A, Ueda A, Ohno S, Baba Y, Kuroiwa Y, Ishigatsubo Y.
  J Neurol. 2010 Jun;257(6):1012-20.
  

  Pubmed

• Behcet's disease and familial Mediterranean fever.
  Takeno M, Ishigatsubo Y.
  Intern Med. 2006;45(13):805-6.

  Pubmed

• Behcet's disease and inflammatory bowel disease.
  Takeno M, Ishigatsubo Y.
  Intern Med. 2004 Mar;43(3):172-3.
  

  Pubmed

• FK506 treatment of noninfectious uveitis.
  Ishioka M, Ohno S, Nakamura S, Isobe K, Watanabe N, Ishigatsubo Y, Tanaka S.
  Am J Ophthalmol. 1994 Dec 15;118(6):723-9.
  

  Pubmed

• Central nervous system toxicity related to FK506 in patients with Behcet's disease.
  Igarashi T, Ishigatsubo Y, Ohno S, Ueda A, Okubo T, Tanaka S, Katsumata Y, Sakane T, Ohno S.
  Ann Rheum Dis. 1994 May;53(5):350-1.
  

  Pubmed

• Pathologically defined neuro-, vasculo-, entero-Behcet's disease.
  Katoh K, Matsunaga K, Ishigatsubo Y, Chiba J, Tani K, Kitamura H, Tani S, Handwerger BS.
  J Rheumatol. 1985 Dec;12(6):1186-90.
  

  Pubmed

• Pathologic features of Behcet's syndrome: a review of Japanese autopsy registry data.
  Lakhanpal S, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T.
  Hum Pathol. 1985 Aug;16(8):790-5.
  

  Pubmed

リウマチ・膠原病－B 関節エコー・画像関連

• On-demand ultrasonography assessment in the most symptomatic joint supports the 8-joint score system for management of rheumatoid arthritis patients.
  Yoshimi R, Takeno M, Toyota Y, Tsuchida N, Sugiyama Y, Kunishita Y, Kishimoto D, Kamiyama R, Minegishi K, Hama M, Kirino Y, Ishigatsubo Y, Ohno S, Ueda A, Nakajima H.
  Mod Rheumatol. 2016 Jul 13:1-9.
  

  Pubmed

• Deep-inspiration breath-hold 18F-FDG-PET/CT is useful for assessment of connective tissue disease associated interstitial pneumonia.
  Uehara T, Takeno M, Hama M, Yoshimi R, Suda A, Ihata A, Ueda A, Tateishi U, Ishigatsubo Y.
  Mod Rheumatol. 2016 26(1):121-7.
  

  Pubmed

• (18)F-FDG and (18)F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis.
  Watanabe T, Takase-Minegishi K, Ihata A, Kunishita Y, Kishimoto D, Kamiyama R, Hama M, Yoshimi R, Kirino Y, Asami Y, Suda A, Ohno S, Tateishi U, Ueda A, Takeno M, Ishigatsubo Y
  Mod Rheumatol. 2016 26(2):180-7.
  

  Pubmed

• Brain FDG-PET reflecting clinical course of depression induced by systemic lupus erythematosus: Two case reports.
  Saito T, Hama M, Chiba Y, Katsuse O, Kamada A, Ikura T, Minegishi K, Ihata A, Takahashi Y, Ishigatsubo Y, Hirayasu Y.
  J Neurol Sci. 2015 Nov 358(1-2):464-6.
  

  Pubmed

• A novel 8-joint ultrasound score is useful in daily practice for rheumatoid arthritis.
  Yoshimi R, Ihata A, Kunishita Y, Kishimoto D, Kamiyama R, Minegishi K, Hama M, Kirino Y, Asami Y, Ohno S, Ueda A, Takeno M, Ishigatsubo Y.
  Mod Rheumatol. 2015 ;25(3):379-85.
  

  Pubmed

• Predicting joint destruction in rheumatoid arthritis with Power Doppler, anti-citrullinated peptide antibody, and joint swelling.
  Kirino Y, Hama M, Takase-Minegishi K, Kunishita Y, Kishimoto D, Yoshimi R, Asami Y, Ihata A, Oba M, Tsunoda S, Ohno S, Ueda A, Takeno M, Ishigatsubo Y.
  Mod Rheumatol. 2015 Mar 4 1-26.
  

  Pubmed

• Ultrasonography predicts achievement of Boolean remission after DAS28-based clinical remission of rheumatoid arthritis.
  Yoshimi R, Hama M, Minegishi K, Kishimoto D, Watanabe T, Kamiyama R, Kirino Y, Asami Y, Ihata A, Tsunoda S, Ueda A, Takeno M, Ishigatsubo Y.
  Mod Rheumatol. 2014 Jul 24(4):590-8.
  

  Pubmed

• Ultrasonography is a potent tool for the prediction of progressive joint destruction during clinical remission of rheumatoid arthritis.
  Yoshimi R, Hama M, Takase K, Ihata A, Kishimoto D, Terauchi K, Watanabe R, Uehara T, Samukawa S, Ueda A, Takeno M, Ishigatsubo Y.
  Mod Rheumatol. 2013 May;23(3):456-65.
  

  Pubmed

• Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab--preliminary data.
  Hama M, Uehara T, Takase K, Ihata A, Ueda A, Takeno M, Shizukuishi K, Tateishi U, Ishigatsubo Y.
  Rheumatol Int. 2012 May;32(5):1327-33.
  

  Pubmed

• Challenges to expanding the clinical application of musculoskeletal ultrasonography (MSUS) among rheumatologists: from a second survey in Japan.
  Hama M, Takase K, Ihata A, Ohno S, Ueda A, Takeno M, Ishigatsubo Y.
  Mod Rheumatol. 2012 Apr;22(2):202-8.
  

  Pubmed

• Simultaneous evaluation of long-lasting knee synovitis in patients undergoing arthroplasty by power Doppler ultrasonography and contrast-enhanced MRI in comparison with histopathology.
  Takase K, Ohno S, Takeno M, Hama M, Kirino Y, Ihata A, Ideguchi H, Mochida Y, Tateishi U, Shizukuishi K, Nagashima Y, Aoki I, Ishigatsubo Y.
  Clin Exp Rheumatol. 2012 Jan-Feb;30(1):85-92.

  Pubmed

• Comparison of low-field dedicated extremity magnetic resonance imaging with articular ultrasonography in patients with rheumatoid arthritis.
  Horikoshi M, Suzuki T, Sugihara M, Kondo Y, Tsuboi H, Uehara T, Hama M, Takase K, Ohno S, Ishigatsubo Y, Yoshida Y, Sagawa A, Ikeda K, Ota T, Matsumoto I, Ito S, Sumida T.
  Mod Rheumatol. 2010 Dec;20(6):556-60.
  

  Pubmed

• Use of musculoskeletal ultrasound in Japan: a survey of practicing rheumatologists.
  Takase K, Ohno S, Ideguchi H, Takeno M, Shirai A, Ishigatsubo Y.
  Mod Rheumatol. 2010 Aug;20(4):376-80.
  

  Pubmed

• Multiple extra-articular synovial cysts complicated with rheumatoid arthritis.
  Kirino Y, Ihata A, Shizukuishi K, Hama M, Takase K, Suda A, Ueda A, Ohno S, Takeno M, Ishigatsubo Y.
  Mod Rheumatol. 2009;19(5):563-6.
  

  Pubmed

• Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis.
  Murakami S, Takeno M, Kirino Y, Kobayashi M, Watanabe R, Kudo M, Ihata A, Ueda A, Ohno S, Watanuki Y, Kaneko T, Ishigatsubo Y.
  Tuberculosis (Edinb). 2009 Mar;89(2):136-41.
  

  Pubmed

• Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs.
  Ideguchi H, Ohno S, Hattori H, Senuma A, Ishigatsubo Y.
  Arthritis Res Ther. 2006;8(3):R76.
  

  Pubmed

リウマチ・膠原病－C その他

• Non-IgG4-related Multifocal Fibrosclerosis.
  Kunishita Y, Yoshimi R, Takeno M, Yamanaka S, Sugiyama Y, Tsuchida N, Kishimoto D, Kamiyama R, Minegishi K, Hama M, Kirino Y, Ishigatsubo Y, Ueda A, Nakajima H.Intern
  Med. 2016;55(17):2497-502.
  

  Pubmed

• Clinical and genetic features of patients with TNFRSF1A variants in Japan: Findings of a nationwide survey
  Ueda N, Ida H, Washio M, Miyahara H, Tokunaga S, Tanaka F, Takahashi H, Kusuhara K, Ohmura K, Nakayama M, Ohara O, Nishikomori R, Minota S, Takei S, Fujii T, Ishigatsubo Y, Tsukamoto H, Tahira T, Horiuchi T.
  Arthritis Rheumatol.2016 Nov;68(11):2760-2771.
  

  Pubmed

• Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study.
  Yamanaka H, Nagaoka S, Lee SK, Bae SC, Kasama T, Kobayashi H, Nishioka Y, Ueki Y, Seto Y, Nishinarita M, Tamura N, Kimura N, Saito K, Tomita T, Nawata Y, Suzuki S, Ishigatsubo Y, Munakata Y, Makino Y, Inoue E, Tanaka Y, Takeuchi T; ENCOURAGE study group.
  Mod Rheumatol. 2016 Sep;26(5):651-61.
  

  Pubmed

• Brain FDG-PET reflecting clinical course of depression induced by systemic lupus erythematosus: Two case reports.
  Saito T, Hama M, Chiba Y, Katsuse O, Kamada A, Ikura T, Minegishi , Ihata A, Takahashi Y, Ishigatsubo Y, Hirayasu Y.
  J Neurol Sci. 2015 Nov 15;358(1-2):464-6.
  

  Pubmed

• Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
  Sakai R, Cho SK, Nanki T, Watanabe K, Yamazaki H, Tanaka M, Koike R, Tanaka Y, Saito K, Hirata S, Amano K, Nagasawa H, Sumida T, Hayashi T, Sugihara T, Dobashi H, Yasuda S, Sawada T, Ezawa K, Ueda A, Fujii T, Migita K, Miyasaka N, Harigai M; REAL Study Group.
  Arthritis Res Ther. 2015 Mar 23;17:74.
  

  Pubmed

• Development of pulmonary and cardiac sarcoidosis during etanercept therapy.
  Miyagi R, Ideguchi H, Soga T, Yamakawa Y, Otsuki H, Niino H, Shiina T, Ueda A, Ishigatsubo Y.
  Int J Rheum Dis. 2013 Oct 31.
  

  Pubmed

• Interstitial pneumonia as an initial manifestation in a patient with late-onset SLE.
  Miyagi R, Ideguchi H, Soga T, Sakamoto K, Niino H, Shiina T, Ueda A, Ishigatsubo Y.
  Int J Rheum Dis. 2014 Jan 23.
  

  Pubmed

• Pregnancy Outcomes in Japanese Patients with SLE: Retrospective Review of 55 Pregnancies at a University Hospital.
  Ideguchi H, Ohno S, Uehara T, Ishigatsubo Y.
  Clin Rev Allergy Immunol. 2013 Feb;44(1):57-64.
  

  Pubmed

• Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
  Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M; REAL Study Group.
  Ann Rheum Dis. 2012 Nov;71(11):1820-6.
  

  Pubmed

• Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan.
  Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, Minota S, Ishigatsubo Y, Ota T, Takei S, Soejima S, Inoue H, Koarada S, Tada Y, Nagasawa K.
  Mod Rheumatol. 2012 Sep;22(5):712-9.
  

  Pubmed

• Preferences of Japanese rheumatoid arthritis patients in treatment decision-making.
  Aoki A, Suda A, Nagaoka S, Takeno M, Ishigatsubo Y, Ashizawa T, Ohde S, Takahashi O, Ohbu S.
  Mod Rheumatol. 2012 Sep 28. [Epub ahead of print]
  

  Pubmed

• Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study.
  Harigai M, Tanaka Y, Maisawa S; JA21963 Study Group.
  J Rheumatol. 2012 Mar;39(3):486-95.
  

  Pubmed

• Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
  Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group.
  J Rheumatol. 2011 Jul;38(7):1258-64.
  

  Pubmed

• Therapeutic angiogenesis in patients with systemic sclerosis by autologous transplantation of bone-marrow-derived cells.
  Ishigatsubo Y, Ihata A, Kobayashi H, Hama M, Kirino Y, Ueda A, Takeno M, Shirai A, Ohno S.
  Mod Rheumatol. 2010 Jun;20(3):263-72.
  

  Pubmed

• Completion rate and compliance of anti-tuberculosis chemoprophylaxis in patients with rheumatic disease receiving tumor necrosis factor antagonists.
  Ideguchi H, Ohno S, Takase K, Kirino Y, Suda A, Ihata A, Ueda A, Takeno M, Nagaoka S, Ishigatsubo Y.
  Clin Exp Rheumatol. 2010 Mar-Apr;28(2):294-5.
  

  Pubmed

• Mycobacterium tuberculosis-specific immunospot assay of pleural exudate mononuclear cells is useful for the exclusion of tuberculous pleuritis in patients with lupus pleuritis.
  Takase K, Ohno S, Ideguchi H, Murakami S, Takeno M, Ishigatsubo Y.
  Lupus. 2009 Feb;18(2):175-7.
  

  Pubmed
  

• The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study.
  Suda A, Nagaoka S, Ohono S, Ideguchi H, Soga T, Ishigatsubo Y.
  Mod Rheumatol. 2008;18(6):609-14.

  Pubmed

• Outcomes after switching from one bisphosphonate to another in 146 patients at a single university hospital.
  Ideguchi H, Ohno S, Takase K, Ueda A, Ishigatsubo Y.
  Osteoporos Int. 2008 Dec;19(12):1777-83.
  

  Pubmed

• Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection.
  Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, Yamazaki E, Sakai R, Tamaru J, Kishi K, Kanamori H, Higashihara M, Hotta T, Ishigatsubo Y.
  Am J Hematol. 2007 Dec;82(12):1106-9.
  

  Pubmed

• Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world.
  Ideguchi H, Ohno S, Hattori H, Ishigatsubo Y.
  Osteoporos Int. 2007 Oct;18(10):1421-7.
  

  Pubmed

• Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
  Ideguchi H, Ohno S, Ishigatsubo Y.
  J Clin Rheumatol. 2007 Apr;13(2):73-8.
  

  Pubmed

• Catastrophic antiphospholipid syndrome associated with malignancies (case report and review of the literature).
  Ideguchi H, Ohno S, Ueda A, Ishigatsubo Y.
  Lupus. 2007;16(1):59-64. Review.
  

  Pubmed

• The incidence of Lofgren's syndrome in Japanese: the number of patients affected, number of patients diagnosed and number of cases reported.
  Ohno S, Ishigatsubo Y.
  Intern Med. 2006;45(12):745-6.
  

  Pubmed

• Systemic sclerosis and pseudomesotheliomatous adenocarcinoma of the lung.
  Yoshimi R, Takeno M, Yamanaka S, Shiina M, Kirino Y, Takeda Y, Sekiguchi A, Kobayashi H, Ihata A, Motoji K, Ohno S, Ueda A, Soga T, Ishigatsubo Y.
  Mod Rheumatol. 2006;16(3):165-8.
  

  Pubmed

• Intestinal manifestations in systemic lupus erythematosus.
  Takeno M, Ishigatsubo Y.
  Intern Med. 2006;45(2):41-2.
  

  Pubmed

• Liver manifestations in systemic lupus erythematosus: high incidence of hemophagocytic syndrome.
  Tsuji T, Ohno S, Ishigatsubo Y.
  J Rheumatol. 2002 Jul;29(7):1576-7.
  

  Pubmed

• Severity of seropositive isolated Raynaud's phenomenon is associated with serological profile.
  Ihata A, Shirai A, Okubo T, Ohno S, Hagiwara E, Ishigatsubo Y.
  J Rheumatol. 2000 Jul;27(7):1686-92.
  

  Pubmed

• Genetic control of PQ prolongation of the electrocardiogram in the mouse immunized with the killed group A streptococci.
  Matsunaga K, Tani K, Katoh K, Ishigatsubo Y, Iwaku T, Tadokoro I, Okuda K.
  J Immunogenet. 1983 Feb;10(1):31-9.

  Pubmed

リウマチ・膠原病－D症例報告

• Non-IgG4-related Multifocal Fibrosclerosis.
  Kunishita Y, Yoshimi R, Takeno M, Yamanaka S, Sugiyama Y, Tsuchida N, Kishimoto D, Kamiyama R, Minegishi K, Hama M, Kirino Y, Ishigatsubo Y, Ueda A, Nakajima H.
  Intern Med. 2016;55(17):2497-502.
  

  Pubmed

• Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate.
  Watanabe K, Takase K, Ohno S, Ideguchi H, Nozaki A, Ishigatsubo Y.
  Mod Rheumatol. 2012 Jun;22(3):470-3.
  

  Pubmed

•  A case of Poncet's disease (tuberculous rheumatism).
  Ideguchi H, Ohno S, Takase K, Tsukahara T, Kaneko T, Ishigatsubo Y.
  Rheumatol Int. 2009 Jul;29(9):1097-9.
  

  Pubmed

• Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab.
  Ideguchi H, Ohno S, Takase K, Hattori H, Kirino Y, Takeno M, Ishigatsubo Y.
  Rheumatology (Oxford). 2007 Oct;46(10):1621-2.
  

  Pubmed

• A case of pure red cell aplasia and systemic lupus erythematosus caused by human parvovirus B19 infection.
  Ideguchi H, Ohno S, Ishigatsubo Y.
  Rheumatol Int. 2007 Feb;27(4):411-4.
  

  Pubmed

• A case of systemic lupus erythematosus complicated with pneumatosis cystoides intestinalis.
  Yamaguchi Y, Ohno S, Yamazaki S, Ideguchi H, Shirai A, Takeno M, Ishigatsubo Y.
  Mod Rheumatol. 2005;15(6):440-4.
  

  Pubmed

• An autopsy case of intravascular lymphomatosis with dermatomyositis.
  Aoki A, Okamura M, Ueda A, Ohno S, Hagiwara E, Tsuji T, Misumi M, Kawachi K, Sasaki T, Inoue Y, Ishigatsubo Y.
  Intern Med. 2002 Mar;41(3):241-4.
  

  Pubmed

• Remitting fasciitis without eosinophilia: a new disease entity? A case report.
  Ohno M, Nagaoka S, Onari K, Kitamura H, Hachiya M, Kondo S, Ishigatsubo Y.
  Rheumatology (Oxford). 2001 Dec;40(12):1428-30.

  Pubmed

• Aortitis syndrome (Takayasu's arteritis) associated with systemic lupus erythematosus.
  Igarashi T, Nagaoka S, Matsunaga K, Katoh K, Ishigatsubo Y, Tani K, Okubo T, Lie JT.
  J Rheumatol. 1989 Dec;16(12):1579-83.
  

  Pubmed

血液関連－A 悪性リンパ腫

• Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy.
  Nakajima Y, Tomita N, Itabashi M, Miyashita K, Watanabe R, Miyazaki T, Tachibana T, Takasaki H, Kawasaki R, Tanaka M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Harano H, Motomura S, Ishigatsubo Y.
  Leuk Res. 2015 ;39(2):198-203.
  

  Pubmed

• Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy.
  Miyashita K, Tomita N, Taguri M, Suzuki T, Ishiyama Y, Ishii Y, Nakajima Y, Numata A, Hattori Y, Yamamoto W, Miyazaki T, Tachibana T, Takasaki H, Matsumoto K, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y.
  Leuk Res. 2015 Aug 29.
  

  Pubmed

• Evaluation of soluble interleukin-2 receptor and serum lactate dehydrogenase in malignant lymphoma.
  Tomita N, Taguri M, Hashimoto C, Takasaki H, Fujimaki K, Motomura S, Koharazawa H, Takemura S, Fujita H, Yamazaki E, Kawasaki R, Taguchi J, Sakai R, Fujisawa S, Hattori Y, Kanamori H, Yamamoto W, Harano H, Ogawa K, Ishigatsubo Y.
  Ann Hematol. 2015 Nov 94(11):1935-7.
  

  Pubmed

• Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass.
  Takasaki H, Yamamoto W, Ishii Y, Takahashi H, Watanabe R, Harada T, Kawasaki R, Hashimoto C, Motomura S, Tomita N, Ishigatsubo Y, Sakai R
  Indian J Hematol Blood Transfus. 2015 Sep 31(3):346-51
  

  Pubmed

• R-CHOP therapy alone for limited-stage follicular lymphoma.
  Tomita N, Suzuki T, Ishiyama Y, Miyashita K, Takahashi H, Numata A, Ito S, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y.
  Leuk Res. 2015 Jun 39(6):582-5.
  

  Pubmed

• Dissemination pattern of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue.
  Ishii Y, Tomita N, Suzuki T, Ishiyama Y, Kishimoto K, Yamamoto E, Koyama S, Hattori Y, Nakajima Y, Motohashi K, Takasaki H, Kawasaki R, Hashimoto C, Takemura S, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y.
  Leuk Lymphoma. 2015 Mar 6 1-3.
  

  Pubmed

• Primary diffuse large B-cell lymphoma of the testis relapsing in the right atrium.
  Yamamoto E, Tomita N, Ishigatsubo Y.
  Br J Haematol. 2015 Feb;168(4):469.
  

  Pubmed

• Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma.
  Tomita N, Hattori Y, Fujisawa S, Hashimoto C, Taguchi J, Takasaki H, Sakai R, Tateishi U, Ishigatsubo Y.
  Ann Hematol. 2015 ;94(3):431-6.
  

  Pubmed

• Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.
  Nakajima Y, Tomita N, Watanabe R, Ishiyama Y, Yamamoto E, Ishibashi D, Itabashi M, Koyama S, Takahashi H, Numata A, Takasaki H, Kawasaki R, Kuwabara H, Tanaka M, Hashimoto C, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y.
  Med Oncol. 2014 Sep 31(9):185.
  

  Pubmed

• Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type.
  Yamazaki E, Tomita N, Koyama S, Ogusa E, Ishii Y, Takahashi H, Miyashita K, Matsuura S, Tachibana T, Takasaki H, Takemura S, Fujimaki K, Sakai R, Fujisawa S, Ishigatsubo Y.
  Med Oncol. 2014 Sep 31(9):149.
  

  Pubmed

• Intrathecal methotrexate prophylaxis and central nervous system relapse in diffuse large B-cell lymphoma patients following R-CHOP.
  Tomita N, Takasaki H, Ishiyama Y, Kishimoto K, Ishibashi D, Koyama S, Ishii Y, Takahashi H, Numata A, Watanabe R, Tachibana T, Ohshima R, Hagihara M, Hashimoto C, Takemura S, Taguchi J, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y.
  Leuk Lymphoma. 2014 Jun 10:1-20.
  

  Pubmed

• HLA-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B cell lymphoma treated by R-CHOP therapy: Retrospective cohort study.
  Yamamoto W, Nakamura N, Tomita N, Takeuchi K, Ishii Y, Takahashi H, Watanabe R, Takasaki H, Motomura S, Kobayashi S, Yokose T, Ishigatsubo Y, Sakai R.
  Leuk Lymphoma. 2014 Feb 17.
  

  Pubmed

• Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.
  Tomita N, Kodama F, Tsuyama N, Sakata S, Takeuchi K, Ishibashi D, Koyama S, Ishii Y, Yamamoto W, Takasaki H, Hagihara M, Kuwabara H, Tanaka M, Hashimoto C, Yamazaki E, Koharazawa H, Fujimaki K, Sakai R, Fujisawa S, Ishigatsubo Y.
  Hematol Oncol. 2014 Feb 11.
  

  Pubmed

• The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients.
  Ishii Y, Tomita N, Tateishi U, Ishiyama Y, Yamamoto E, Hattori Y, Hagihara M, Yamazaki E, Ishigatsubo Y.
  Med Oncol. 2014 Mar 31(3):880.
  

  Pubmed

• Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
  Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Hattori Y, Motohashi K, Takasaki H, Ohshima R, Hashimoto C, Yamazaki E, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y.
  Eur J Haematol. 2014 Mar 92(3):204-10.
  

  Pubmed

• The MIB-1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy.
  Yamamoto E, Tomita N, Sakata S, Tsuyama N, Takeuchi K, Nakajima Y, Miyashita K, Tachibana T, Takasaki H, Tanaka M, Hashimoto C, Koharazawa H, Fujimaki K, Taguchi J, Harano H, Motomura S, Ishigatsubo Y.
  Cancer Sci. 2013 Dec 104(12):1670-4.
  

  Pubmed

• Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.
  Tomita N, Takasaki H, Fujisawa S, Miyashita K, Ogusa E, Kishimoto K, Matsuura S, Sakai R, Koharazawa H, Yamamoto W, Fujimaki K, Fujita H, Ishii Y, Taguchi J, Kuwabara H, Motomura S, Ishigatsubo Y.
  J Clin Exp Hematop. 2013 53(2):121-5.
  

  Pubmed

• The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era.
  Watanabe R, Tomita N, Matsumoto C, Hattori Y, Matsuura S, Takasaki H, Hashimoto C, Fujita H, Fujisawa S, Ishigatsubo Y.
  J Clin Exp Hematop. 2013 53(2):107-14.
  

  Pubmed

• Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
  Watanabe R, Tomita N, Kishimoto K, Koyama S, Ogusa E, Ishii Y, Miyashita K, Matsuura S, Fujisawa S, Hattori Y, Takasaki H, Fujita A, Ohshima R, Kuwabara H, Hashimoto C, Fujimaki K, Sakai R, Ishigatsubo Y.
  Leuk Res. 2013 Oct. 37(10):1208-12.
  

  Pubmed

• Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age.
  Takasaki H, Hashimoto C, Fujita A, Matsumoto K, Taguchi J, Kuwabara H, Yamazaki E, Koharazawa H, Fujita H, Fujisawa S, Ishii Y, Yamamoto W, Motomura S, Tomita N, Ishigatsubo Y, Sakai R.
  Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):404-9.
  

  Pubmed

• R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma.
  Tomita N, Takasaki H, Miyashita K, Fujisawa S, Ogusa E, Matsuura S, Kishimoto K, Numata A, Fujita A, Ohshima R, Kuwabara H, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Fujimaki K, Taguchi J, Sakai R, Ishigatsubo Y.
  Br J Haematol. 2013 May;161(3):383-8.
  

  Pubmed

• Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era.
  Takahashi H, Tomita N, Sakata S, Tsuyama N, Hashimoto C, Ohshima R, Matsuura S, Ogawa K, Yamamoto W, Kameda Y, Enaka M, Inayama Y, Kasahara M, Takekawa Y, Onoda N, Motomura S, Ishigatsubo Y, Takeuchi K.
  Eur J Haematol. 2013 Apr;90(4):286-90.

  Pubmed

• Clinicopathological analysis of mediastinal large B-cell lymphoma and classical Hodgkin lymphoma of the mediastinum.
  Yamamoto W, Nakamura N, Tomita N, Ishii Y, Takasaki H, Hashimoto C, Motomura S, Yamazaki E, Ohshima R, Numata A, Ishigatsubo Y, Sakai R.
  Leuk Lymphoma. 2013 May;54(5):967-72.
  

  Pubmed

• Role of 18F-fluoride PET/CT in the assessment of multiple myeloma: initial experience.
  Nishiyama Y, Tateishi U, Shizukuishi K, Shishikura A, Yamazaki E, Shibata H, Yoneyama T, Ishigatsubo Y, Inoue T.
  Ann Nucl Med. 2013 Jan;27(1):78-83.
  

  Pubmed

• Maximum standard uptake value at the biopsy site during (18)F-fluorodeoxyglucose positron emission tomography does not predict the proliferation potential of tumor cells in extranodal natural killer/t cell lymphoma, nasal type.
  Ishii Y, Tomita N, Sakata S, Takeuchi K, Tateishi U, Watanabe R, Sakai R, Ishigatsubo Y.
  Acta Haematol. 2012;128(2):110-2.
  

  Pubmed

• Retrospective study of the utility of FLIPI/FLIPI-2 for follicular lymphoma patients treated with R-CHOP.
  Numata A, Tomita N, Fujimaki K, Tanaka M, Hashimoto C, Oshima R, Matsumoto K, Matsuura S, Yamamoto W, Motomura S, Ishigatsubo Y.
  J Clin Exp Hematop. 2012;52(1):77-9.
  

  Pubmed

• Phase II study of CHOP-GR therapy in diffuse large B-cell lymphoma.
  Takemura S, Tomita N, Koharazawa H, Fujimaki K, Harano H, Hyo R, Yamazaki E, Hashimoto C, Miyazaki T, Ishigatsubo Y.
  Int J Hematol. 2012 Aug;96(2):241-6.
  

  Pubmed

• Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.
  Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M; Real Study Group.
  Arthritis Care Res (Hoboken). 2012 Aug;64(8):1125-34.
  

  Pubmed

• SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma.
  Tomita N, Sakai R, Fujisawa S, Fujimaki K, Taguchi J, Hashimoto C, Ogawa K, Yamazaki E, Ishigatsubo Y.
  Cancer Sci. 2012 Aug;103(8):1518-23.
  

  Pubmed

• Clinical features of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue.
  Ishii Y, Tomita N, Takasaki H, Ogusa E, Hattori Y, Matsuura S, Matsumoto C, Takemura S, Kuwabara H, Ishigatsubo Y.
  Hematol Oncol. 2012 Dec;30(4):186-9.
  

  Pubmed

• Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population.
  Ogusa E, Tomita N, Ishii Y, Takasaki H, Hattori Y, Matsumoto C, Ishigatsubo Y.
  Hematol Oncol. 2013 Mar;31(1):18-21.

  Pubmed

• Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
  Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, Hashimoto C, Tamura K, Sato K, Ishigatsubo Y.
  Cancer. 2012 Sep 1;118(17):4166-72.
  

  Pubmed

• Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era.
  Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K.
  Cancer Sci. 2012 Feb;103(2):245-51.
  

  Pubmed

• Central nervous system involvement in diffuse large B-cell lymphoma.
  Yamamoto W, Tomita N, Watanabe R, Hattori Y, Nakajima Y, Hyo R, Hashimoto C, Motomura S, Ishigatsubo Y.
  Eur J Haematol. 2010 Jul;85(1):6-10.
  

  Pubmed

• SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma.
  Watanabe R, Tomita N, Takeuchi K, Sakata S, Tateishi U, Tanaka M, Fujita H, Inayama Y, Ishigatsubo Y.
  Leuk Lymphoma. 2010 Feb;51(2):279-83.
  

  Pubmed

• Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.
  Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, Miyamoto K, Kikuchi A, Hyo R, Yakushijin Y, Masaki Y, Fujii S, Hayashi T, Ishigatsubo Y, Miura I.
  Haematologica. 2009 Jul;94(7):935-43.
  

  Pubmed

• Diffuse large B cell lymphoma without immunoglobulin light chain restriction by flow cytometry.
  Tomita N, Takeuchi K, Hyo R, Hashimoto C, Takemura S, Taguchi J, Fujita H, Fujisawa S, Ogawa K, Motomura S, Ishigatsubo Y.
  Acta Haematol. 2009;121(4):196-201.
  

  Pubmed

• The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
  Hyo R, Tomita N, Takeuchi K, Aoshima T, Fujita A, Kuwabara H, Hashimoto C, Takemura S, Taguchi J, Sakai R, Fujita H, Fujisawa S, Ogawa K, Motomura S, Suzuki R, Ishigatsubo Y.
  Hematol Oncol. 2010 Mar;28(1):27-32.
  

  Pubmed

• Features of primary extranodal lymphoma in Kanagawa, a human T-cell leukemia virus type 1 nonendemic area in Japan.
  Fujita A,Tomita N,Fujita H,Motohashi K,Hyo R,Yamazaki E, Hattori M,Fujisawa S,Kanamori H,Igawa K,Motomura S,Kodama F, Ishigatsubo Y.
  Med Oncol. 2009;26(1):49-54.
  

  Pubmed

• Adjuvant radiotherapy to an initial bulky mass in diffuse large B-cell lymphoma: lack of survival benefit.
  Tomita N, Kodama F, Motomura S, Itoh S, Ohshima R, Hyo R, Kawano T, Hashimoto C, Takemura S, Yamazaki E, Fujita H, Fujisawa S, Ogawa K, Kanamori H, Ishigatsubo Y.
  Int J Lab Hematol. 2008 Feb;30(1):53-7.
  

  Pubmed

• Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: Relationship with type of latent Epstein-Barr virus infection.
  Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, Yamazaki E, Sakai R, Tamaru JI, Kishi K, Kanamori H, Higashihara M, Hotta T, Ishigatsubo Y.
  Am J Hematol. 2007 Dec;82(12):1106-9.

  Pubmed

• Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
  Tomita N, Motomura S, Hyo R, Takasaki H, Takemura S, Taguchi J, Fujisawa S, Ogawa K, Ishigatsubo Y, Takeuchi K.
  Cancer. 2007 Mar 15;109(6):1146-51.

  Pubmed

• Secondary central nervous system lymphoma.
  Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y.
  Int J Hematol. 2006 Aug;84(2):128-35.

  Pubmed

• Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma.
  Tomita N, Kodama F, Oshima R, Hashimoto C, Koharazawa H, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Kanamori H, Motomura S, Ishigatsubo Y.
  Leuk Lymphoma. 2006 Jun;47(6):1041-7.

  Pubmed

• Outcome of involved-field radiotherapy for stage 1 follicular lymphoma.
  Tomita N, Kodama F, Motohashi K, Fujita A, Hyo R, Hashimoto C, Takemura S, Yamazaki E, Taguchi J, Sakai R, Fujisawa S, Kanamori H, Motomura S, Ishigatsubo Y, Takeuchi K.
  Int J Hematol. 2006 May;83(4):370-2.

  Pubmed

• Prognostic factors in diffuse large B-cell lymphoma treated by risk-adopted therapy.
  Tomita N, Kodama F, Motomura S, Koharazawa H, Fujita H, Harano H, Kanamori H, Ishigatsubo Y.
  Intern Med. 2006;45(5):247-52.

  Pubmed

• Clinical features and outcome in HCV-positive aggressive non-Hodgkin's lymphoma.
  Tomita N, Kodama F, Takabayashi M, Kawano T, Yamaji S, Fujimaki K, Fujisawa S, Kanamori H, Motomura S, Ishigatsubo Y.
  Leuk Lymphoma. 2003 Jul;44(7):1159-64.

  Pubmed

• Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
  Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y.
  Cancer. 2002 Aug 1;95(3):576-80.

  Pubmed

• Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
  Tomita N, Kodama F, Sakai R, Koharasawa H, Hattori M, Taguchi J, Fujita H, Tanabe J, Fujisawa S, Fukawa H, Harano H, Kanamori H, Miyashita H, Matsuzaki M, Ogawa K, Motomura S, Maruta A, Ishigatsubo Y.
  Leuk Lymphoma. 2000 Jul;38(3-4):335-43.

  Pubmed

血液関連－B 造血細胞移植

• Retrospective Study of Incidence and Prognostic Significance of Eosinophilia after Allogeneic Hematopoietic Stem Cell Transplantation: Influence of Corticosteroid Therapy.
  Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H.
  Turk J Haematol. 2016 Sep 5;33(3):196-201.
  

  Pubmed

• Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
  Yamamoto W, Fujii E, Matsumoto K, Yamamoto E, Aoki J, Tanaka M, Ishigatsubo Y, Kanamori H.
  Int J Hematol. 2016 Apr 103(4):444-52.
  

  Pubmed

• Successful Engraftment and Durable Graft-versus-host Disease Control with Haploidentical Peripheral Blood and a Short-term Conditioning Regimen for Primary Graft Failure.
  Tachibana T, Yamamoto E, Kawasaki R, Koharazawa H, Ishibashi D, Nakajima Y, Tanaka M, Matsumoto K, Ishigatsubo Y, Fujisawa S.
  Intern Med. 2015 54(21):2749-52.
  

  Pubmed

• Clinical significance of the administration of cytarabine or thiotepa in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia.
  Tachibana T, Tanaka M, Hagihara M, Kawasaki R, Yamazaki E, Koharazawa H, Taguchi J, Tomita N, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H.
  Int J Hematol. 2015 Oct 102(4):451-9.
  

  Pubmed

• Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
  Numata A, Kajiyama R, Itabashi M, Ishii Y, Yamamoto W, Motohashi K, Matsumoto K, Hagihara M, Ishigatsubo Y, Fujisawa S.
  Leuk Lymphoma. 2016 57(1):201-2.
  

  Pubmed

• Successful pregnancy and delivery via in vitro fertilization with cryopreserved and thawed embryo transfer in an acute myeloid leukemia patient after allogeneic bone marrow transplantation.
  Nakajima Y, Kuwabara H, Kishimoto K, Numata A, Motohashi K, Tachibana T, Tanaka M, Yamashita N, Ishigatsubo Y, Fujisawa S.
  Int J Hematol. 2014 Nov 28.
  

  Pubmed

• Predictive value of risk assessment scores in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic stem cell transplantation.
  Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H.
  Am J Hematol. 2014 May 21.
  

  Pubmed

• Validation of the European Group for Blood and Marrow Transplantation (EBMT) risk score in patients receiving allogeneic hematopoietic stem cell transplantation at a single center in Japan.
  Numata A, Tanaka M, Matsumoto K, Takasaki H, Tachibana T, Fujimaki K, Sakai R, Fujisawa S, Tomita N, Fujita H, Maruta A, Ishigatsubo Y, Kanamori H.
  Clin Transplant. 2014 Mar 21.
  

  Pubmed

• Disseminated Cunninghamella bertholletiae infection with septic pulmonary embolism after allogeneic bone marrow transplantation.
  Matsumoto K, Yamamoto W, Ohgusa E, Tanaka M, Maruta A, Ishigatsubo Y, Kanamori H.
  Transpl Infect Dis. 2014 Apr. 16(2):304-6.
  

  Pubmed

• Human herpesvirus-6 encephalopathy after hematopoietic stem cell transplantation and class I human leukocyte antigen.
  Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H.
  Clin Transplant. 2014 Mar 1. 28(5):540-5.
  

  Pubmed

• Prognostic index for relapsed acute leukemia after allogeneic stem cell transplantation.
  Matsumoto K, Yamamoto W, Ogusa E, Ishigatsubo Y, Kanamori H.
  Leuk Lymphoma. 2014 Feb 21.
  

  Pubmed

• Recovery of natural killer cells and prognosis after cord blood transplantation.
  Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H.
  Leuk Res. 2013 Nov 37(11):1522-6.
  

  Pubmed

• Drug-induced liver injury after allogeneic bone marrow transplantation.
  Tachibana T, Nozaki A, Enaka M, Yamamoto E, Kawasaki R, Koharazawa H, Hagihara M, Ishibashi D, Nakajima Y, Kuwabara H, Tomita N, Ishigatsubo Y, Fujisawa S.
  Int J Hematol. 2013 Sep 15.
  

  Pubmed

• Clinical significance of pre- and one year post- transplant serum ferritin among adult transplant recipients.
  Tachibana T, Tanaka M, Numata A, Matsumoto K, Tomita N, Fujimaki K, Taguchi J, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H.
  Leuk Lymphoma. 2013 Sep 11.
  

  Pubmed

• Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.
  Motohashi K, Suzuki T, Kishimoto K, Numata A, Nakajima Y, Tachibana T, Ohshima R, Kuwabara H, Tanaka M, Tomita N, Ishigatsubo Y, Fujisawa S.
  Int J Hematol. 2013 Jun 26. [Epub ahead of print]
  

  Pubmed

• Concentrated Ascites Reinfusion Therapy for Sinusoidal Obstructive Syndrome After Hematopoietic Stem Cell Transplantation.
  Takahashi H, Sakai R, Fujita A, Kuwabara H, Hattori Y, Matsuura S, Ohshima R, Hagihara M, Tomita N, Ishigatsubo Y, Fujisawa S.
  Artif Organs. 2013 May 20.
  

  Pubmed

• Impact of pretransplant serum ferritin on outcome in adult patients receiving cord blood transplant for acute leukemia.
  Matsumoto K, Yamamoto W, Ogusa E, Sugimoto E, Maruta A, Ishigatsubo Y, Kanamori H.
  Leuk Lymphoma. 2013 Jun 24. [Epub ahead of print] No abstract available.
  

  Pubmed

• Multicenter validation of scoring system of pre-transplant serum ferritin and disease risk in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplant.
  Tachibana T, Tanaka M, Yamazaki E, Numata A, Takasaki H, Kuwabara H, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H.
  Leuk Lymphoma. 2013 Jun;54(6):1318-20.
  

  Pubmed

• Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia.
  Miyazaki T, Fujita H, Fujimaki K, Hosoyama T, Watanabe R, Tachibana T, Fujita A, Matsumoto K, Tanaka M, Koharazawa H, Taguchi J, Tomita N, Sakai R, Fujisawa S, Kanamori H, Ishigatsubo Y.
  Leuk Res. 2012 Aug;36(8):998-1003.
  

  Pubmed

• The impact of the dose of natural killer cells in the graft on severe acute graft-versus-host disease after unrelated bone marrow transplantation.
  Tanaka M, Kobayashi S, Numata A, Tachibana T, Takasaki H, Maruta A, Ishigatsubo Y, Kanamori H.
  Leuk Res. 2012 Jun;36(6):699-703.

  Pubmed

• Pretransplant serum ferritin has a prognostic influence on allogeneic transplant regardless of disease risk.
  Tachibana T, Tanaka M, Numata A, Takasaki H, Ito S, Ohshima R, Hagihara M, Yamazaki E, Tomita N, Fujimaki K, Taguchi J, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H.
  Leuk Lymphoma. 2012 Mar;53(3):456-61.
  

  Pubmed

• A prognostic score with pretransplant serum ferritin and disease status predicts outcome following reduced-intensity SCT.
  Tanaka M, Tachibana T, Numata A, Takasaki H, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H.
  Bone Marrow Transplant. 2012 Apr;47(4):596-7.
  

  Pubmed

• Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy.
  Takasaki H, Tanaka M, Tachibana T, Numata A, Fujimaki K, Sakai R, Fujisawa S, Tomita N, Fujita H, Maruta A, Ishigatsubo Y, Kanamori H.
  Int J Hematol. 2012 Mar;95(3):291-8.
  

  Pubmed

• Long-term outcome of human herpesvirus-6 encephalitis after allogeneic stem cell transplantation.
  Sakai R, Kanamori H, Motohashi K, Yamamoto W, Matsuura S, Fujita A, Ohshima R, Kuwabara H, Tanaka M, Fujita H, Maruta A, Ishigatsubo Y, Fujisawa S.
  Biol Blood Marrow Transplant. 2011 Sep;17(9):1389-94.
  

  Pubmed

• Pre-SCT serum ferritin is a prognostic factor in adult AML, but not ALL.
  Tachibana T, Tanaka M, Takasaki H, Numata A, Maruta A, Ishigatsubo Y, Kanamori H.
  Bone Marrow Transplant. 2011 Sep;46(9):1268-9.
  

  Pubmed

• Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies.
  Tachibana T, Tanaka M, Takasaki H, Numata A, Ito S, Watanabe R, Hyo R, Ohshima R, Hagihara M, Sakai R, Fujisawa S, Tomita N, Fujita H, Maruta A, Ishigatsubo Y, Kanamori H.
  Int J Hematol. 2011 Mar;93(3):368-74.
  

  Pubmed

• Serum ferritin and disease status at transplantation predict the outcome of allo-SCT in patients with AML or myelodysplastic syndrome.
  Tachibana T, Takasaki H, Tanaka M, Maruta A, Hyo R, Ishigatsubo Y, Kanamori H.
  Bone Marrow Transplant. 2011 Jan;46(1):150-1.
  

  Pubmed

• Myeloablative hematopoietic stem cell transplantation for myelodysplastic syndrome in patients younger than 55 years: impact of comorbidity and disease burden on the long-term outcome.
  Kanamori H, Enaka M, Ito S, Motohashi K, Hagihara M, Oshima R, Sakai R, Fujisawa S, Tanaka M, Fujimaki K, Fujita H, Ishigatsubo Y, Maruta A.
  Int J Lab Hematol. 2010 Apr;32(2):222-9.
  

  Pubmed

• Cerebral venous sinus thrombosis after allogeneic stem cell transplantation.
  Motohashi K, Hagihara M, Ito S, Tachibana T, Takasaki H, Tanaka M, Maruta A, Ishigatsubo Y, Kanamori H.
  Int J Hematol. 2010 Jan;91(1):154-6.
  

  Pubmed

• Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients aged 50 years and over.
  Fujimaki K, Tanaka M, Takasaki H, Hyo R, Kawano T, Sakai R, Fujita H, Fujisawa S, Kanamori H, Maruta A, Ishigatsubo Y.
  Intern Med. 2008;47(5):379-83.
  

  Pubmed

• Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.
  Fujimaki K, Taguchi J, Fujita H, Hattori M, Yamazaki E, Takahashi N, Fujisawa S, Kanamori H, Maruta A, Ishigatsubo Y.
  Bone Marrow Transplant. 2004 Apr;33(8):789-92.
  

  Pubmed

• Clinical significance of fragmented red cells after allogeneic bone marrow transplantation.
  Kanamori H, Takaishi Y, Takabayashi M, Tanaka M, Yamaji S, Tomita N, Fujimaki K, Fujisawa S, Watanabe S, Matsuzaki M, Ishigatsubo Y.
  Int J Hematol. 2003 Feb;77(2):180-4.

  Pubmed

• Immune reconstitution assessed during five years after allogeneic bone marrow transplantation.
  Fujimaki K, Maruta A, Yoshida M, Kodama F, Matsuzaki M, Fujisawa S, Kanamori H, Ishigatsubo Y.
  Bone Marrow Transplant. 2001 Jun;27(12):1275-81.

  Pubmed

• Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction.
  Fujimaki K, Maruta A, Yoshida M, Sakai R, Tanabe J, Koharazawa H, Kodama F, Asahina S, Minamizawa M, Matsuzaki M, Fujisawa S, Kanamori H, Ishigatsubo Y.
  Bone Marrow Transplant. 2001 Feb;27(3):307-10.

  Pubmed

• Long-term liver function of recipients with hepatitis G virus infection after bone marrow transplantation.
  Maruta A, Tanabe J, Hashimoto C, Kato K, Kanamori H, Fukawa H, Miyashita H, Fujisawa S, Fujita H, Matsuzaki M, Motomura S, Kodama F, Ookawa S, Mohri H, Ishigatsubo Y.
  Bone Marrow Transplant. 1999 Aug;24(4):359-63.

  Pubmed

血液関連－C 白血病

• Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia.
  Yamazaki E, Kanamori H, Itabashi M, Ogusa E, Numata A, Yamamoto W, Ito S, Tachibana T, Hagihara M, Matsumoto K, Koharazawa H, Taguchi J, Tomita N, Fujimaki K, Fujita H, Fujisawa S, Ogawa K, Ishigatsubo Y.
  Leuk Lymphoma. 2017 Jan;58(1):104-109.
  

  Pubmed

• Acute leukemia during pregnancy: an investigative survey of the past 11 years.
  Nakajima Y, Hattori Y, Ito S, Ohshima R, Kuwabara H, Machida S, Shirasugi Y, Miyazaki K, Sakai R, Tomita N, Ando K, Higashihara M, Ishigatsubo Y, Fujisawa S.
  Int J Lab Hematol. 2014 May 21.
  

  Pubmed

• European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.
  Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, Kishimoto K, Hashimoto C, Itabashi M, Ishibashi D, Nakajima Y, Tachibana T, Kawasaki R, Kuwabara H, Koharazawa H, Yamazaki E, Tomita N, Sakai R, Fujita H, Kanamori H, Ishigatsubo Y.
  Cancer Sci. 2014 Jan 105(1):105-9.
  

  Pubmed

• The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.
  Watanabe T, Hotta C, Koizumi S, Miyashita K, Nakabayashi J, Kurotaki D, Sato GR, Yamamoto M, Nakazawa M, Fujita H, Sakai R, Fujisawa S, Nishiyama A, Ikezawa Z, Aihara M, Ishigatsubo Y, Tamura T.
  Cancer Res. 2013 Nov 15 73(22):6642-53.
  

  Pubmed

• Lymphocyte recovery on day 100 after allogeneic hematopoietic stem cell transplantation predicts non-relapse mortality in patients with acute leukemia or myelodysplastic syndrome.
  Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H.
  Leuk Lymphoma. 2013 Jul 11. [Epub ahead of print]
  

  Pubmed

• Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.
  Fujita H, Asou N, Iwanaga M, Hyo R, Nomura S, Kiyoi H, Okada M, Inaguma Y, Matsuda M, Yamauchi T, Ohtake S, Izumi T, Nakaseko C, Ishigatsubo Y,
  Shinagawa K, Takeshita A, Miyazaki Y, Ohnishi K, Miyawaki S, Naoe T; The Japan Adult Leukemia Study Group.
  Cancer Sci. 2013 Jul 10. doi: 10.1111/cas.12230. [Epub ahead of print]
  

  Pubmed

• Successful azacitidine treatment with increase of regulatory T cells for relapsed acute myeloid leukemia after allogeneic stem cell transplant.
  Yamamoto W, Tachibana T, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H.
  Leuk Lymphoma. 2013 Feb 11. [Epub ahead of print]
  

  Pubmed

• Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia.
  Koharazawa H, Kanamori H, Sakai R, Hashimoto C, Takemura S, Hattori M, Taguchi J, Fujimaki K, Tomita N, Fujita H, Fujisawa S, Harano H, Ogawa K, Motomura S, Maruta A, Ishigatsubo Y.
  Leuk Lymphoma. 2008 Nov;49(11):2133-40.

  Pubmed

• Significance of micromegakaryocytes in Philadelphia chromosome-positive acute lymphoblastic leukemia.
  Kobayashi S, Maruta A, Yamamoto T, Fujisawa S, Fukawa H, Kanamori H, Matsuzaki M, Motomura S, Kodama F, Ishigatsubo Y.
  Leukemia. 2000 Jul;14(7):1327-9.

  Pubmed

血液関連－D その他

• A retrospective analysis of obstetric patients with idiopathic thrombocytopenic purpura: a single center study.
  Fujita A, Sakai R, Matsuura S, Yamamoto W, Ohshima R, Kuwabara H, Okuda M, Takahashi T, Ishigatsubo Y, Fujisawa S.
  Int J Hematol. 2010 Oct;92(3):463-7.
  

  Pubmed

• Strong inverse correlation between serum TPO level and platelet count in essential thrombocythemia.
  Tomita N, Motomura S, Sakai R, Fujimaki K, Tanabe J, Fukawa H, Harano H, Kanamori H, Ogawa K, Mohri H, Maruta A, Kodama F, Ishigatsubo Y, Tahara T, Kato T.
  Am J Hematol. 2000 Mar;63(3):131-5.

  Pubmed

血液関連－E 症例報告

• Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
  Numata A, Kajiyama R, Itabashi M, Ishii Y, Yamamoto W, Motohashi K, Matsumoto K, Hagihara M, Ishigatsubo Y, Fujisawa S.
  Leuk Lymphoma. 2016;57(1):201-2.

  Pubmed

• Successful treatment of a pregnant woman with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  Nakajima Y, Kuwabara H, Hattori Y, Ohshima R, Sakai R, Kitagawa M, Tomita N, Ishigatsubo Y, Fujisawa S.
  Int J Hematol. 2013 Mar;97(3):427-9.

  Pubmed

• Successful disease control with l-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure.
  Takahashi H, Sakai R, Hattori Y, Ohshima R, Kuwabara H, Hagihara M, Enaka M, Nozawa A, Tomita N, Ishigatsubo Y, Fujisawa S.
  Leuk Lymphoma. 2013 Mar;54(3):662-4.
  

  Pubmed

• Successful Treatment With Third Stem Cell Transplant From an Allogeneic Donor for a Patient With Relapsed Diffuse Large B-Cell Lymphoma.
  Takasaki H, Ishii Y, Yamamoto W, Tsuchihashi H, Motomura S, Tomita N, Ishigatsubo Y, Sakai R.
  Exp Clin Transplant. 2013 Apr;11(2):199-202
  

  Pubmed

• Thrombosis at ascending aorta following chemotherapy in a patient with acute myeloid leukemia.
  Tachibana T, Tanaka M, Ishigatsubo Y, Kanamori H.
  Int J Hematol. 2012 Sep;96(3):293-4.
  

  Pubmed

• Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation.
  Tachibana T, Tanaka M, Takasaki H, Numata A, Fujisawa S, Maruta A, Harada H, Mori H, Ishigatsubo Y, Kanamori H.
  Int J Hematol. 2011 Dec;94(6):580-2.
  

  Pubmed

• Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion.
  Tachibana T, Numata A, Tanaka M, Motohashi K, Fujisawa S, Fujita H, Sakai R, Tomita N, Maruta A, Ishigatsubo Y, Kanamori H.
  Leuk Lymphoma. 2011 Jul;52(7):1376-9.
  

  Pubmed

• Primary hepatic peripheral T-cell lymphoma treated with corticosteroid.
  Miyashita K, Tomita N, Oshiro H, Matsumoto C, Nakajima Y, Ito S, Matsumoto K, Fujita H, Ishigatsubo Y.
  Intern Med. 2011;50(6):617-20.
  

  Pubmed

• Aberrant CD20 expression in angioimmunoblastic T-cell lymphoma.
  Tachibana T, Tomita N, Furuya M, Yamanaka S, Takeuchi K, Nakamura N, Fujita H, Ishigatsubo Y.
  Intern Med. 2011;50(5):495-9.
  

  Pubmed

• A New Three-Way Translocation t(4;11;7)(q21;q23;q22) in a Mixed-Phenotype Acute Leukemia.
  Takasaki H, Tachibana T, Tanaka M, Maruta A, Ishigatsubo Y, Kanamori H.
  Case Report Hematol. 2011;2011:148482.
  

  Pubmed

• Cutaneous zygomycosis caused by Cunninghamella bertholletiae in a patient with chronic myelogenous leukemia in blast crisis.
  Motohashi K, Ito S, Hagihara M, Maruta A, Ishigatsubo Y, Kanamori H.
  Am J Hematol. 2009 Jul;84(7):447-8.

  Pubmed

• Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.
  Ishizawa J, Fujita H, Iguchi M, Tachibana T, Taguchi J, Ishigatsubo Y.
  Int J Hematol. 2007 Apr;85(3):242-5.

  Pubmed

• Acute myelomonocytic leukemia with dysplastic bone marrow eosinophils showing t(5;17)(q13;q11) and a secondary chromosomal aberration, inv(16)(p13q22).
  Sakai R, Fujimaki K, Yamazaki E, Sakamoto H, Kanamori H, Miura I, Ishigatsubo Y.
  Int J Hematol. 2006 Dec;84(5):417-20.

  Pubmed

• Non-Hodgkin's lymphoma presenting as multiple bone lesions and hypercalcemia.
  Takasaki H, Kanamori H, Takabayashi M, Yamaji S, Koharazawa H, Taguchi J, Fujimaki K, Ishigatsubo Y.
  Am J Hematol. 2006 Jun;81(6):439-42.

  Pubmed

• Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma after cord blood stem cell transplantation following autologous peripheral blood stem cell transplantation.
  Sakai R, Fujisawa S, Fujimaki K, Kanamori H, Ishigatsubo Y.
  Bone Marrow Transplant. 2006 Mar;37(5):537-8.

  Pubmed

• Idiopathic thrombocytopenic purpura and myasthenia gravis after fludarabine treatment for chronic lymphocytic leukemia.
  Fujimaki K, Takasaki H, Koharazawa H, Takabayashi M, Yamaji S, Baba Y, Kanamori H, Ishigatsubo Y.
  Leuk Lymphoma. 2005 Jul;46(7):1101-2.

  Pubmed

• Resolution of atopic dermatitis following allogeneic bone marrow transplantation for chronic myelogenous leukemia.
  Koharazawa H, Kanamori H, Takabayashi M, Yamaji S, Taguchi J, Fujimaki K, Ishigatsubo Y.
  Bone Marrow Transplant. 2005 Jun;35(12):1223-4.
  

  Pubmed

• Human herpesvirus-6 encephalitis after unrelated cord blood transplantation.
  Tanaka M, Taguchi J, Hyo R, Kawano T, Hashimoto C, Motomura S, Kodama F, Kobayashi S, Okabe G, Maruta A, Nagao T, Ishigatsubo Y.
  Leuk Lymphoma. 2005 Apr;46(4):561-6.
  

  Pubmed

• Atypical Burkitt lymphoma arising from follicular lymphoma: demonstration by polymerase chain reaction following laser capture microdissection and by fluorescence in situ hybridization on paraffin-embedded tissue sections.
  Tomita N, Nakamura N, Kanamori H, Fujimaki K, Fujisawa S, Ishigatsubo Y, Nomura K.
  Am J Surg Pathol. 2005 Jan;29(1):121-4.
  

  Pubmed

• Epstein-Barr virus-associated extranodal NK/T-cell lymphoma following mosquito bites in an elderly patient without prior hypersensitivity.
  Tomita N, Kanamori H, Fujimaki K, Fujisawa S, Ishigatsubo Y.
  Leuk Lymphoma. 2004 Oct;45(10):2153-5.
  

  Pubmed

• Long-term cytogenetic remission with ubenimex monotherapy in a case of chronic myeloid leukemia.
  Kanamori H, Takasaki H, Takabayashi M, Yamaji S, Koharazawa H, Fujimaki K, Taguchi J, Ishigatsubo Y.
  Anticancer Drugs. 2004 Aug;15(7):729-31.
  

  Pubmed

• Cutaneous mucormycosis during induction chemotherapy for acute lymphocytic leukemia.
  Takabayashi M, Sakai R, Sakamoto H, Kakinuma M, Iemoto Y, Kanamori H, Ishigatsubo Y.
  Leuk Lymphoma. 2004 Jan;45(1):199-200.
  

  Pubmed

• Pulmonary embolism and thrombotic thrombocytopenic purpura in acute promyelocytic leukemia treated with all-trans retinoic acid.
  Fujita H, Takemura S, Hyo R, Tanaka M, Koharazawa H, Fujisawa S, Kanamori H, Ishigatsubo Y.
  Leuk Lymphoma. 2003 Sep;44(9):1627-9.
  

  Pubmed

• Involvement of central nervous system in prolymphocytoid transformation of chronic lymphocytic leukemia.
  Kuwabara H, Kanamori H, Takasaki H, Takabayashi M, Yamaji S, Tomita N, Fujimaki K, Fujisawa S, Ishigatsubo Y.
  Leuk Lymphoma. 2003 Jul;44(7):1235-7.

  Pubmed

• Successful treatment with intermediate dose cytosine arabinoside for myelodysplastic syndrome with acute myelofibrosis.
  Takabayashi M, Sakai R, Kanamori H, Ishigatsubo Y.
  Leuk Lymphoma. 2003 May;44(5):891-2.

  Pubmed

• Double Philadelphia chromosomes-positive acute lymphocytic leukemia.
  Takasaki H, Kanamori H, Takabayashi M, Yamaji S, Tomita N, Fujimaki K, Fujisawa S, Ishigatsubo Y.
  Leuk Lymphoma. 2003 Apr;44(4):735-6.

  Pubmed

• Merkel cell carcinoma developing after antithymocyte globulin and cyclosporine therapy for aplastic anemia.
  Takabayashi M, Sakai R, Sakamoto H, Iemoto Y, Kanamori H, Inayama Y, Ishigatsubo Y.
  Anticancer Drugs. 2003 Mar;14(3):251-3.

  Pubmed

• Increased exhaled nitric oxide in bronchiolitis obliterans organizing pneumonia after allogeneic bone marrow transplantation.
  Kanamori H, Fujisawa S, Tsuburai T, Yamaji S, Tomita N, Fujimaki K, Miyashita A, Suzuki S, Ishigatsubo Y.
  Transplantation. 2002 Nov 15;74(9):1356-8.

  Pubmed

• Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature.
  Kanamori H, Tanaka M, Kawaguchi H, Yamaji S, Fujimaki K, Tomita N, Fujisawa S, Ishigatsubo Y.
  Am J Hematol. 2002 Sep;71(1):41-4.

  Pubmed

• Acute lymphoblastic leukemia with t(1;9;22)(q32;q34;q11).
  Fujisawa S, Kanamori H, Takabayashi M, Tanaka M, Yamaji S, Tomita N, Fujimaki K, Ishigatsubo Y.
  Int J Hematol. 2002 May;75(4):443-5.

  Pubmed

• Relapse of acute promyelocytic leukemia after 10 years long-term remission.
  Fujisawa S, Kanamori H, Tanaka M, Yamaji S, Taguchi J, Ishigatsubo Y.
  Leuk Lymphoma. 2002 Mar;43(3):679-80.

  Pubmed

• Posttransplantation Epstein-Barr viral meningitis in a patient with chronic myelogenous leukemia.
  Kanamori H, Fujisawa S, Yamaji S, Tanaka M, Tomita N, Fujimaki K, Ishigatsubo Y.
  Int J Hematol. 2001 Dec;74(4):473-4.

  Pubmed

• Therapy-related CD7+ acute myeloid leukemia with trisomy 8 following acute monocytic leukemia.
  Tanaka M, Kanamori H, Yamaji S, Fujimaki K, Tomita N, Fujisawa S, Ishigatsubo Y.
  Anticancer Drugs. 2001 Sep;12(8):681-2.

  Pubmed

• Granulomatous tubulointerstitial nephritis induced by all-trans retinoic acid.
  Tomita N, Kanamori H, Fujita H, Maruta A, Naitoh A, Nakamura S, Ota Y, Nozue N, Kihara M, Ishigatsubo Y.
  Anticancer Drugs. 2001 Sep;12(8):677-80.

  Pubmed

• Bronchiolitis obliterans organizing pneumonia (BOOP) with suspected liver graft-versus-host disease after allogeneic bone marrow transplantation.
  Kanamori H, Mishima A, Tanaka M, Yamaji S, Fujisawa S, Koharazawa H, Nishikawa M, Matsuzaki M, Mohri H, Ishigatsubo Y.
  Transpl Int. 2001 Aug;14(4):266-9.

  Pubmed

• Primary splenic Hodgkin's disease with remarkable granulomatous reaction.
  Tanaka M, Kanamori H, Fujisawa S, Taguchi J, Nakatani Y, Kawano N, Mohri H, Ishigatsubo Y.
  Leuk Lymphoma. 2001 Mar;41(1-2):225-7.

  Pubmed

• Subcutaneous extramedullary hematopoiesis in a patient with secondary myelofibrosis following polycythemia vera.
  Tanaka M, Kanamori H, Yamaji S, Mishima A, Yamazaki E, Taguchi J, Aoba M, Fujisawa S, Mohri H, Ishigatsubo Y.
  Leuk Lymphoma. 2001 Jan;40(3-4):437-40.

  Pubmed

• Interferon-alpha-induced pure red cell aplasia following chronic myelogenous leukemia.
  Tomita N, Motomura S, Ishigatsubo Y.
  Anticancer Drugs. 2001 Jan;12(1):7-8.

  Pubmed

• Chronic myelomonocytic leukemia with t(1;3)(p36;q21) and a synchronous gastric cancer.
  Fujisawa S, Harano H, Yamazaki E, Motomura S, Mohri H, Ishigatsubo Y.
  Am J Med Sci. 2000 Apr;319(4):258-60.

  Pubmed

• Acute minimally differentiated myeloid leukemia (M0) with inv(3)(q21q26).
  Fujisawa S, Tanabe J, Harano H, Kanamori H, Motomura S, Mohri H, Ishigatsubo Y.
  Leuk Lymphoma. 1999 Nov;35(5-6):627-30.

  Pubmed

• Improvement of quality of life after splenectomy in an HTLV-I carrier with T-cell prolymphocytic leukemia.
  Sakai R, Maruta A, Tomita N, Taguchi J, Fujisawa S, Ogawa K, Motomura S, Kodama F, Mohri H, Ishigatsubo Y.
  Leuk Lymphoma. 1999 Nov;35(5-6):607-11.

  Pubmed

• De novo acute myelogenous leukemia with trilineage myelodysplasia associated with t(8;21)(q22;q22).
  Fujisawa S, Togawa J, Tanaka M, Koharazawa H, Aoba M, Fujita H, Murata T, Kanamori H, Matsuzaki M, Mohri H, Ishigatsubo Y.
  Intern Med. 1999 Jul;38(7):607-11.
  

  Pubmed

呼吸器関連－A 喘息・COPD

• Chronic Use of Theophylline and Mortality in Chronic Obstructive Pulmonary Disease: A Meta-analysis.
  Horita N, Miyazawa N, Kojima R, Inoue M, Ishigatsubo Y, Kaneko T.
  Arch Bronconeumol. 2016 May 52(5):233-238.
  

  Pubmed

• Impact of Corticosteroids on Mortality in Patients with Acute Respiratory Distress Syndrome: A Systematic Review and Meta-analysis.
  Horita N, Hashimoto S, Miyazawa N, Fujita H, Kojima R, Inoue M, Ueda A, Ishigatsubo YI, Kaneko T.
  Intern Med. 2015 54(12):1473-9.
  

  Pubmed

• Vitamin D binding protein genotype variants and risk of chronic obstructive pulmonary disease: A meta-analysis.
  Horita N, Miyazawa N, Tomaru K, Inoue M, Ishigatsubo Y, Kaneko T.
  Respirology. 2014 Dec 9.
  

  Pubmed

• Measurement of eNO with portable analyzer might improve the management of persistent cough at primary care practice in Japan.
  Watanabe K, Shinkai M, Shinoda M, Hara Y, Yamaguchi N, Rubin BK, Ishigatsubo Y, Kaneko T.
  Clin Respir J. 2014 Oct 13.
  

  Pubmed

• Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studies.
  Horita N, Miyazawa N, Kojima R, Inoue M, Ishigatsubo Y, Ueda A, Kaneko T.
  Respir Res. 2014 Jul 16 15(1):80.
  

  Pubmed

• Minimum Clinically Important Difference in Diffusing Capacity of the Lungs for Carbon Monoxide Among Patients with Severe and Very Severe Chronic Obstructive Pulmonary Disease.
  Horita N, Miyazawa N, Kojima R, Inoue M, Ishigatsubo Y, Kaneko T.
  COPD. 2014 Jun 10.
  

  Pubmed

• Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease.
  Horita N, Miyazawa N, Morita S, Kojima R, Inoue M, Ishigatsubo Y, Kaneko T.
  Respir Res. 2014 Apr 3 15(1):37.
  

  Pubmed

• Evaluation of the Chronic Obstructive Pulmonary Disease Assessment Test in Japanese Outpatients.
  Horita N, Yomota M, Sasaki M, Morita S, Shinkai M, Ishigatsubo Y, Kaneko T.
  Clin Respir J. 2014 Apr. 8(2):213-9.
  

  Pubmed

• Pathology of asthma.
  Kudo M, Ishigatsubo Y, Aoki I.
  Front Microbiol. 2013 Sep 10;4:263.
  

  Pubmed

• Small, Moderate, and Large Changes, and the Minimum Clinically Important Difference in the University of California, San Diego Shortness of Breath Questionnaire.
  Horita N, Miyazawa N, Morita S, Kojima R, Kimura N, Kaneko T, Ishigatsubo Y.
  COPD. 2013 Jul 25. [Epub ahead of print]
  

  Pubmed

• Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study.
  Horita N, Miyazawa N, Morita S, Kojima R, Kimura N, Kaneko T, Ishigatsubo Y.
  Respir Res. 2013 Jun 3;14:62.
  

  Pubmed

• Depression in Japanese Patients with Chronic Obstructive Pulmonary Disease. A Cross-Sectional Study.
  Horita N, Kaneko T, Shinkai M, Yomota M, Morita S, Rubin BK, Ishigatsubo Y.
  Respir Care. 2013 Jul;58(7):1196-203.
  

  Pubmed

呼吸器関連－B 肺がん

• Monocyte nadir is a possible indicator for neutrophil nadir during lung cancer chemotherapy.
  Moriyama Y, Horita N, Kudo M, Shinkai M, Fujita H, Yamanaka T, Ishigatsubo Y, Kaneko T.
  Clin Respir J. 2015 Aug
  

  Pubmed

• Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature.
  Watanabe K, Shinkai M, Goto H, Yoshikawa S, Yamaguchi N, Hara Y, Shinoda M, Moriyama Y, Rubin BK, Ishigatsubo Y, Kaneko T.
  Tumori. 2013 Jul-Aug 99(4):172e-6e.
  

  Pubmed

• Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation.
  Ishii Y, Yamazaki E, Ishiyama Y, Yamamoto E, Hattori Y, Hagihara M, Tomita N, Ishigatsubo Y.
  Int J Hematol. 2013 Dec 98(6):723-8.
  

  Pubmed

• PET/CT Findings for Bone Marrow Carcinosis Because of Lung Adenocarcinoma.
  Watanabe K, Shinkai M, Nagai K, Yamaguchi N, Ishigatsubo Y, Kaneko T.
  J Thorac Oncol. 2013 Nov 8(11):1456-7.
  

  Pubmed

• Long-term Remission Achieved via Combined Chemotherapy and Radiotherapy in a Non-resectable Granulocyte Colony-stimulating Factor Producing Pleomorphic Carcinoma of the Lung.
  Yamamoto M, Manabe S, Moriyama Y, Ishii H, Tanaka S, Takahashi R, Tomaru K, Kobayashi N, Kudo M, Sasaki M, Inayama Y, Kaneko T, Ishigatsubo Y.
  Intern Med. 2013 52(19):2259-63.
  

  Pubmed

• Preoperative Chemotherapy Is Effective for Stage III Resectable Non-Small-Cell Lung Cancer: Metaanalysis of 16 Trials.
  Horita N, Miyazawa N, Morita S, Kojima R, Kimura N, Kaneko T, Ishigatsubo Y.
  Clin Lung Cancer. 2013 May 9
  

  Pubmed

• The Impact of a Negative History of Smoking on Survival in Patients with Non-Small Cell Lung Cancer Detected with Clinic-based Screening Programs.
  Nagakura H, Nishikawa M, Kusano N, Saito M, Morita S, Kaneko T, Ishigatsubo Y.
  Intern Med. 2012;51(22):3115-8. Epub 2012 Nov 15.
  

  Pubmed

• Synchronous lung and gastric cancers successfully treated with carboplatin and pemetrexed: a case report.
  Sato T, Tomaru K, Koide T, Masuda M, Yamamoto M, Miyazawa N, Inayama Y, Kaneko T, Ishigatsubo Y.
  J Med Case Rep. 2012 Aug 31;6(1):266.

  Pubmed

呼吸器関連－C 結核・呼吸器感染症

• The effectiveness of sputum pH analysis in the prediction of response to therapy in patients with pulmonary tuberculosis.
  Masuda M, Sato T, Sakamaki K, Kudo M, Kaneko T, Ishigatsubo Y.
  PeerJ. 2015 Nov
  

  Pubmed

• Currently Used Low-Dose Pyrazinamide Does Not Increase Liver-Injury in the First Two Months of Tuberculosis Treatment.
  Horita N, Miyazawa N, Yoshiyama T, Kojima R, Ishigatsubo Y, Kaneko T.
  Intern Med. 2015 54(18):2315-20.
  

  Pubmed

• Mycobacterium shinjukuense Lung Disease that was Successfully Treated with Antituberculous Drugs.
  Watanabe K, Shinkai M, Yamaguchi N, Shinoda M, Hara Y, Ishigatsubo Y, Kaneko T.
  Intern Med. 2013 52(23):2653-5.
  

  Pubmed

• Sensitivity and Specificity of the Streptococcus Pneumoniae Urinary Antigen Test for Unconcentrated Urine from Adult Patients with Pneumonia: A Meta-Analysis.
  Horita N, Miyazawa N, Kojima R, Kimura N, Inoue M, Ishigatsubo Y, Kaneko T.
  Respirology. 2013 Nov. 18(8):1177-83.
  

  Pubmed

• Poor performance status is a strong predictor for death in patients with smear-positive pulmonary TB admitted to two Japanese hospitals.
  Horita N, Miyazawa N, Yoshiyama T, Kojima R, Omori N, Kaneko T, Ishigatsubo Y.
  Trans R Soc Trop Med Hyg. 2013 Jul;107(7):451-6.

  Pubmed

• Development and validation of a tuberculosis prognostic score for smear-positive in-patients in Japan.
  Horita N, Miyazawa N, Yoshiyama T, Sato T, Yamamoto M, Tomaru K, Masuda M, Tashiro K, Sasaki M, Morita S, Kaneko T, Ishigatsubo Y.
  Int J Tuberc Lung Dis. 2013 Jan;17(1):54-60.
  

  Pubmed

• Decreased activities of daily living is a strong risk factor for liver injury by anti-tuberculosis drugs.
  Horita N, Miyazawa N, Yoshiyam T, Tsukahara T, Takahashi R, Tsukiji J, Kato H, Kaneko T, Ishigatsubo Y.
  Respirology. 2013 Apr;18(3):474-9.
  

  Pubmed

• The presence of pretreatment cavitations and the bacterial load on smears predict tuberculosis infectivity negative conversion judged on sputum smear or culture.
  Horita N, Miyazawa N, Yoshiyama T, Kojima R, Omori N, Inoue M, Kaneko T, Ishigatsubo Y.
  Intern Med. 2012;51(24):3367-72. Epub 2012 Dec 15.
  

  Pubmed

• Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study.
  Inoue S, Watanuki Y, Kaneko T, Sato T, Miyazawa N, Kaneko T, Ishigatsubo Y, Morita S, Natsumeda Y, Mizushima S.
  BMJ Open. 2011 Jul 18;1(1):e000105.
  

  Pubmed

• Clinical efficacy of carbapenems on hospital-acquired pneumonia in accordance with the Japanese Respiratory Society Guidelines for management of HAP.
  Ito M, Kaneko T, Goto H, Yamaguchi N, Fujisawa S, Ono S, Morita S, Miyazawa N, Kanamori H, Watanuki Y, Ishigatsubo Y.
  J Infect Chemother. 2011 Dec;17(6):770-5.
  

  Pubmed

• Esophagomediastinal and esophagobronchial fistulas associated with invasive aspergillosis.
  Kato S, Inoue S, Inamori M, Miyazawa N, Sato T, Kobayashi N, Mishina K, Sasaki M, Ishigatsubo Y, Nakajima A.
  Endoscopy. 2010;42 Suppl 2:E48-9.

  Pubmed

呼吸器関連－D 症例報告

• An Autopsy Case Report of Malignant Pleural Mesothelioma with Deciduoid Features.
  Ushio R, Yamamoto M, Shibata Y, Ishii H, Watanabe K, Takahashi R, Sato T, Kudo M, Miyake A, Kaneko T, Ishigatsubo Y.
  Intern Med. 2015 54(22):2915-7.
  

  Pubmed

• Intrapulmonary Schwannoma Diagnosed With Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: Case Report.
  Watanabe K, Shinkai M, Shinoda M, Ishigatsubo Y, Kaneko T.
  Arch Bronconeumol. 2014 Jun 3.
  

  Pubmed

• Severe obliterative bronchitis associated with Stevens-Johnson syndrome.
  Woo T, Saito H, Yamakawa Y, Komatsu S, Onuma S, Okudela K, Nozawa A, Aihara M, Ikezawa Z, Ishigatsubo Y.
  Intern Med. 2011;50(22):2823-7.
  

  Pubmed

• Metastatic brain mass caused by slow-growing small-cell lung cancer: differential vascular endothelial growth factor expression in primary and metastatic tumor.
  Inoue S, Oshiro H, Watanuki Y, Miyazawa N, Kudo M, Goto H,Tsukiji J, Kaneko T, Ishigatsubo Y.
  Clin Lung Cancer. 2007 Jul;8(7):436-8.

  Pubmed

• Pulmonary hyalinizing granuloma with laryngeal and subcutaneous involvement: report of a case successfully treated with glucocorticoids.
  Shinohara T, Kaneko T, Miyazawa N, Nakatani Y, Nishiyama H, Shoji A, Ishigatsubo Y.
  Intern Med. 2004 Jan;43(1):69-73.

  Pubmed

• Lipoid pneumonia.
  Ikehara K, Suzuki M, Tsuburai T, Ishigatsubo Y.
  Lancet. 2002 Apr 13;359(9314):1300.
  

  Pubmed

アレルギー関連

• Isoniazid and food interactions: --fish, cheese, and wine.
  Kaneko T, Ishigatsubo Y.
  Intern Med. 2005 Nov;44(11):1120-1.
  

  Pubmed

感染症関連－A HIV関連

• Effect of adiponectin-encoding gene ADIPOQ single nucleotide polymorphisms +45 and +276 on serum lipid levels after antiretroviral therapy in Japanese patients with HIV-1-infection.
  Kato H, Ohata A, Samukawa S, Ueda A, Ishigatsubo Y.
  J Int Med Res. 2016 Apr 44(2):297-306
  

  Pubmed

• HIV-1 CRF01_AE and Subtype B Transmission Networks Crossover: A New AE/B Recombinant Identified in Japan.
  Hosaka M, Fujisaki S, Masakane A, Hattori J, Shiino T, Gatanaga H, Shigemi U, Okazaki R, Hachiya A, Matsuda M, Ibe S, Iwatani Y, Yokomaku Y, Sugiura W; Japanese Drug Resistance HIV-1 Surveillance Network Team.
  AIDS Res Hum Retroviruses. 2016 May;32(5):412-9.
  

  Pubmed

• Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan.
  Hattori J, Shiino T, Gatanaga H, Yoshida S, Watanabe D, Minami R, Sadamasu K, Kondo M, Mori H, Ueda M, Tateyama M, Ueda A, Kato S, Ito T, Oie M, Takata N, Hayashida T, Nagashima M, Matsuda M, Ibe S, Ota Y, Sasaki S, Ishigatsubo Y, Tanabe Y, Koga I, Kojima Y, Yamamoto M, Fujita J, Yokomaku Y, Koike T, Shirasaka T, Oka S, Sugiura W.
  Antiviral Res. 2010 Oct;88(1):72-9.
  

  Pubmed

• Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid
  expressing IL-12.
  Tsuji T, Hamajima K, Fukushima J, Xin KQ, Ishii N, Aoki I, Ishigatsubo Y, Tani K, Kawamoto S, Nitta Y, Miyazaki J, Koff WC, Okubo T, Okuda K.
  J Immunol. 1997 Apr 15;158(8):4008-13.
  

  Pubmed

• Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen.
  Tsuji T, Hamajima K, Ishii N, Aoki I, Fukushima J, Xin KQ, Kawamoto S, Sasaki S, Matsunaga K, Ishigatsubo Y, Tani K, Okubo T, Okuda K.
  Eur J Immunol. 1997 Mar;27(3):782-7.
  

  Pubmed

• HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine.
  Tsuji T, Fukushima J, Hamajima K, Ishii N, Aoki I, Bukawa H, Ishigatsubo Y, Tani K, Okubo T, Dorf ME, Okuda K.
  Immunology. 1997 Jan;90(1):1-6.
  

  Pubmed

• Dual infection with HIV-1 Thai subtype B and E.
  Xin KQ, Ma XH, Crandall KA, Bukawa H, Ishigatsubo Y, Kawamoto S, Okuda K.
  Lancet. 1995 Nov 18;346(8986):1372-3.
  

  Pubmed

感染症関連－B 結核関連

• The effectiveness of sputum pH analysis in the prediction of response to therapy in patients with pulmonary tuberculosis.
  Masuda M, Sato T, Sakamaki K, Kudo M, Kaneko T, Ishigatsubo Y.
  PeerJ. 2015 Nov 26;3:e1448. doi: 10.7717/peerj.1448. eCollection 2015.
  

  Pubmed

• Risk factors for liver injury with an elevated serum bilirubin concentration caused by antituberculous drugs.
  Kato H, Horita N, Miyazawa N, Yoshiyama T, Ueda A, Ishigatsubo Y.
  Intern Med. 2013 52(19):2209-14.
  

  Pubmed

• Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis.
  Murakami S, Takeno M, Kirino Y, Kobayashi M, Watanabe R, Kudo M, Ihata A, Ueda A, Ohno S, Watanuki Y, Kaneko T, Ishigatsubo Y.
  Tuberculosis (Edinb). 2009 Mar;89(2):136-41.
  

  Pubmed

• Diagnosis of tuberculous meningitis due to detection of ESAT-6-specific gamma interferon production in cerebrospinal fluid enzyme-linked immunospot assay.
  Murakami S, Takeno M, Oka H, Ueda A, Kurokawa T, Kuroiwa Y, Ishigatsubo Y.
  Clin Vaccine Immunol. 2008 May;15(5):897-9.
  

  Pubmed

感染症関連－C その他

• High frequency of β-lactamase-negative, ampicillin-resistant strains of Haemophilus influenzae in patients with chronic bronchitis in Japan.
  Inoue S, Watanuki Y, Miyazawa N, Kudo M, Sato T, Kobayashi N, Mishina K, Sasaki M, Kaneko T, Ishigatsubo Y.
  J Infect Chemother. 2010 Feb;16(1):72-5.
  

  Pubmed

• The efficacy of high-dose penicillin for community-acquired pneumonia diagnosed by pneumococcal urine antigen test.
  Oka H, Ueda A, Watanuki Y, Tsukiji J, Kuroda H, Akashi S, Hirai Y, Fuyuki T, Kaneko T, Ishigatsubo Y.
  J Infect Chemother. 2009 Apr;15(2):108-12.
  

  Pubmed

• Potential clinical benefit of the in situ hybridization method for the diagnosis of sepsis.
  Kudo M, Matsuo Y, Nakasendo A, Inoue S, Goto H, Tsukiji J, Watanuki Y, Ueda A, Kaneko T, Ishigatsubo Y.
  J Infect Chemother. 2009 Feb;15(1):23-6.
  

  Pubmed

• Varicella pneumonia in adults.
  Kaneko T, Ishigatsubo Y.
  Intern Med. 2004 Dec;43(12):1105-6.
  

  Pubmed

• Diagnosis of nocardial infection by microscopic analysis of infected specimens.
  Kaneko T, Ishigatsubo Y.
  Intern Med. 2002 Nov;41(11):915-6.
  

  Pubmed

• Increasing incidence of invasive pulmonary aspergillosis and its early diagnosis.
  Kaneko T, Ishigatsubo Y.
  Intern Med. 2001 Nov;40(11):1073-4.
  

  Pubmed

• Immune response induced by airway sensitization after influenza A virus infection depends on timing of antigen exposure in mice.
  Yamamoto N, Suzuki S, Suzuki Y, Shirai A, Nakazawa M, Suzuki M, Takamasu T, Nagashima Y, Minami M, Ishigatsubo Y.
  J Virol. 2001 Jan;75(1):499-505.
  

  Pubmed

• Contribution of CpG motifs to the immunogenicity of DNA vaccines.
  Klinman DM, Yamshchikov G, Ishigatsubo Y.
  J Immunol. 1997 Apr 15;158(8):3635-9.
  

  Pubmed

感染症関連－D 症例報告

• Salmonella enterica serovar Ohio septic arthritis and bone abscess in an immunocompetent patient: a case report.
  Kato H, Ueda A, Tsukiji J, Sano K, Yamada M, Ishigatsubo Y.
  J Med Case Rep. 2012 Jul 17;6(1):204.
  

  Pubmed